User:Mr. Ibrahem/Ubrogepant

Ubrogepant, sold under the brand name Ubrelvy, is a medication used to treat migraine attacks. This includes whether or not an aura was present. It is not used for migraine prevention. It is taken by mouth.

Common side effects include nausea, tiredness and dry mouth. Safety during pregnancy or breastfeeding is unclear. Use is not recommended together with strong CYP3A4 inhibitors or inducers. It is a small-molecule calcitonin gene-related peptide receptor antagonist.

Ubrogepant was approved for medical use in the United States in 2019. In the United States it costs about 87 USD per 100 mg tablet as of 2021. In Canada this amount is 15 CAD as of 2024. It has not been approved in Europe as of 2021.